Status: Recruiting
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian cancer, and other advanced solid tumors . This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase-1b Dose Expansion (Part 2). In each part, patients who meet specific eligibility criteria will be enrolled.
Participants needed: 210
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Duboce Biopharmaceuticals, Inc.Updated: Aug 21, 2026Locations: 5
Eligibility criteria
Must be ≥18 years of age at the time consent is signed. [+2]
Has a diagnosis of immunodeficiency. [+9]